A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma

References

• AdelrothERakSHaahtelaTRecombinant humanized mAb E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitisJ Allergy Clin Immunol2000106253910932067
   PubMed Web of Science ®Google Scholar
• AntonicelliLBuccaCNeriMAsthma severity and medical resource utilizationEur Respir J20042372372915176687
   PubMed Web of Science ®Google Scholar
• AyresJGHigginsBChilversEREfficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergis asthmaAllergy2004597018
   Web of Science ®Google Scholar
• BatemanEDBousheyHABousquetJCan guideline- defined asthma control be achieved? The Gaining Optiman Asthma ControL studyAm J Resp Crit Care Med20041708364415256389
   PubMed Web of Science ®Google Scholar
• BouletL-PChapmanKRCoteJInhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic responseAm J Respir Crit Care Med19971551835409196083
   PubMed Web of Science ®Google Scholar
• BousquetJCabreraPBerkmanNEffect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy200560302815679714
   PubMed Web of Science ®Google Scholar
• BrownRTurkFDalePCost-effectivenes of omalizumab in patients with severe persistent allergic asthmaAllergy2007621495317298423
   PubMed Web of Science ®Google Scholar
• BuhlRHanfGSolerMThe anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthmaEur Respir J20022010889412449159
   PubMed Web of Science ®Google Scholar
• BuhlRSolerMMatzJOmalizumab provides long-term control in patients with moderate-to-severe allergic asthmaEur Respir J20022073812166585
   PubMed Web of Science ®Google Scholar
• BusseWWBanks-SchiegelSWenzelSPathophysiology of severe asthmaJ Allergy Clin Immunol200010610334211112883
   PubMedGoogle Scholar
• BusseWWCoffmanRLGelfandEWMechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell productsAm J Respir Crit Care Med1995152388937599853
   PubMed Web of Science ®Google Scholar
• CasaleTOmalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitisJ Allergy Clin Immunol20061171344016387596
   PubMed Web of Science ®Google Scholar
• CasaleTCondemiJMillerSDrhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR)Ann Allergy Asthma Immunol19998275
   Web of Science ®Google Scholar
• ChangTWThe pharmacological basis of anti-IgE therapyNat Biotechnol2000181576310657120
   PubMed Web of Science ®Google Scholar
• ChangTWShiungYYAnti-IgE as a mastcell stabilizing therapeutic agentJ Allergy Clin Immunol200611712031216750976
   PubMed Web of Science ®Google Scholar
• CruzAALimaFSarinhoESafety on anti-immunoglobulin E theraphy with omalizumab in allergic patients at risk of geohelminth infectionClin Exp Allergy20073719720717250692
   PubMed Web of Science ®Google Scholar
• D’AmatoGTherapy of allergic bronchial asthma with anti-IgE monoclonal antibodyExpert Opin Biol Ther20033371612662149
   PubMed Web of Science ®Google Scholar
• D’AmatoGRole of anti-igE monoclonal antibody (omalizumab) in the treatment of allergic respiratory diseasesEur J Pharmacol2006533302716464445
   PubMed Web of Science ®Google Scholar
• D’AmatoGBucchioniEOldaniVTreating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (omalizumab)Treat Respir Med20065393817154668
   PubMedGoogle Scholar
• D’AmatoGHolgateSTThe impact of air pollution on respiratory health2002Sheffield UKEuropean Respiratory Monograph n.21
   Google Scholar
• D’AmatoGLiccardiGNoschesePAnti-IgE. Monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseasesCurr Drug Targets Inflamm Allergy20043227915379589
   PubMedGoogle Scholar
• DenizYGuptaNSafety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibodyClin Reviews Allergy Immunol2005293148
   PubMed Web of Science ®Google Scholar
• DjukanovicRWilsonSJKraftMThe effects of anti-IgE (omalizumab) treatment on airways inflammation in allergic asthmaAm J Respir Crit Care Med20041705839315172898
   PubMed Web of Science ®Google Scholar
• European Respiratory Society and the European Lung FoundationEuropean Lung white book2003Brussels, BelgiumEuropean Repiratory Society and The European Lung Foundation
   Google Scholar
• FahyJVYeadonMDiamantZThe anti-IgE treatment strategy for asthmaNew and exploratory therapeutic agents for asthma: lung biology in health and disease2000Marcel Dekker32942
   Google Scholar
• FahyJVFlemingHEWongHHThe effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjectsAm J Respir Crit Care Med19971551828349196082
   PubMed Web of Science ®Google Scholar
• FregoneseLPaelAvan SchadewijkAExpression of the high affinity IgE receptor (FceRI) is increased in fatal asthma [abstract]Am J Respir Crit Care Med2004169A297
   Google Scholar
• GodardPChanezLSiraudinLCosts of asthma are correlated with severity: a 1-yr prospective studyEur Respir J20021861711843329
   PubMed Web of Science ®Google Scholar
• GuiteHFDundasRBurneyPGJRisk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthmaThorax1999543027
   Web of Science ®Google Scholar
• HamiltonRGMarcotteGVSainiSSImmunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapyJ Immunol Methods2005303819116045925
   PubMed Web of Science ®Google Scholar
• HolgateSBousquetJWenzelSEfficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortalityCurr Med Res Opin2001172334011922396
   PubMed Web of Science ®Google Scholar
• HolgateSCasaleTWenzelSThe anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJ Allergy Clin Immunol20051154596515753888
   PubMed Web of Science ®Google Scholar
• HollowajJAHolgateSTSemperAEExpression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthmaJ Allergy Clin Immunol200110710091811398078
   PubMed Web of Science ®Google Scholar
• HoltPGMacaubasCStumblesPAThe role of allergy in the development of asthmaNature1999402B117
   Web of Science ®Google Scholar
• HumbertMBeaskeyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy603091615679715
   PubMed Web of Science ®Google Scholar
• KoppMVBrauburgerJRiedingerFThe effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitisJ Allergy Clin Immunol20021107283512417881
   PubMed Web of Science ®Google Scholar
• KuehrJBrauburgerJZielenSEfficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJ Allergy Clin Immunol20021092748011842297
   PubMed Web of Science ®Google Scholar
• LoddenkemperRGibsonGJSibilleYEuropean lung white book. The first comprehensive survey on respiratory health in Europe. European Respiratory Society (ERS)ERSJ2003
   Google Scholar
• MankadSVBurksAWOmalizumab: other indications and unanswered questionsClin Reviews in Allergy Immunol2005291730
   PubMed Web of Science ®Google Scholar
• MacGlashanDWBochnerBSAdelmanDCDown-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibodyJ Immunol19971581438459013989
   PubMed Web of Science ®Google Scholar
• MasoliMFabianDHoltSThe global burden of asthma: executive summary of the GINA Dissemination Committee reportAllergy20045946878
   Web of Science ®Google Scholar
• MilgromHBergerWNayakATreatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)Pediatrics20011083645
   PubMed Web of Science ®Google Scholar
• MooreWCBleeckerERCurran-EverettDCharacterization of the severe asthma phenotype by the National Heart, Lung and Blood Institute’s Severe asthma Research ProgramJ Allergy Clin Immunol20071194051317291857
   PubMed Web of Science ®Google Scholar
• National Institutes of Health/National Heart Lung and Blood Institute (NHLBI)Global Initiate for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report March 20062006Bethesda, MD, USA
   Google Scholar
• NiebauerKDewildeSFox-RushbyJImpact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthmaAnn Allergy Asthma Immunol2006963162616498854
   PubMed Web of Science ®Google Scholar
• NovakNBieberTAllergic and nonallergic forms of atopic diseasesJ Allergy Clin Immunol20031122526212897728
   PubMed Web of Science ®Google Scholar
• PartridgeMRvan der MolenTMyrsethSEAttitudes and action of asthma patients on regular maintenance theraphy: the INSPIRE studyBMC Pulm Med200661316772035
   PubMedGoogle Scholar
• PlewakoHArvidssonMPetrusonKThe effect of omalizumab on nasal allergic inflammationJ Allergy Clin Immunol2002110687112110823
   PubMed Web of Science ®Google Scholar
• RabeKFAdachiMLaiCKWorldwide severity and control of asthma in children and adults: the global asthma insights and reality surveysJ Allergy Clin Immunol200411440715241342
   PubMed Web of Science ®Google Scholar
• ReddSCAsthma in the Unites States: burden and current theoriesEnviron Health Perspect2002110Suppl 45576012194886
   PubMed Web of Science ®Google Scholar
• Serra-BatlesJPlazaVMorejonECosts of asthma according to the degree of severityEur Respir J199812132269877485
   PubMed Web of Science ®Google Scholar
• SolerMMatzJTownleyRThe anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEur Respir J2001182546111529281
   PubMed Web of Science ®Google Scholar
• StrunkRCBloombergGROmalizumab for asthmaNew Engl J Med200635426899516790701
   PubMed Web of Science ®Google Scholar
• TogiasACorrenJShapiroGAnti-IgE treatment reduces skin test (ST) reactivityJ Allergy Clin Immunol1998101S171
   PubMed Web of Science ®Google Scholar
• ToughSCHesselPARuffMFeatures that distinguish those who die from asthma from community controls with asthmaJ Asthma199835657659860086
   PubMed Web of Science ®Google Scholar
• TurkFKaySHigginsVThe economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational studyThorax200560Suppl 1121
   Google Scholar
• VignolaAMHumbertMBousquetJEfficacy and tolerability of anti-immunoglobulin E therapy with olamizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy2004597091715180757
   PubMed Web of Science ®Google Scholar
• Van GanseELaforestLPietriGPersistent asthma: disease control, resource utilisation and direct costsEur Respir J200220260712212953
   PubMed Web of Science ®Google Scholar
• WalkerSMonteilMPhelanKAnti-IgE for chronic asthma in adults and children (Review) The Cochrane Collaboration 2006Issue 2John Wiley & Sons, Ltd
   Google Scholar
• WenzelSSevere asthma in adultsAm J Respir Crit Care Med20051721496015849323
   PubMed Web of Science ®Google Scholar
• WenzelSEWestcottJYLarsenGLBronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responsesJ Allergy Clin Immunol19918754081993813
   PubMed Web of Science ®Google Scholar